---
annotation-target: nihms-1767266.pdf
---


>%%
>```annotation-json
>{"created":"2022-09-07T06:08:01.516Z","updated":"2022-09-07T06:08:01.516Z","document":{"title":"Artificial Intelligence in Lymphoma PET Imaging:: A Scoping Review (Current Trends and Future Directions)","link":[{"href":"urn:x-pdf:bfc9fa0d2dfeaf41b27539013de3cb13"},{"href":"vault:/hematology-theroy/papers/hematology_deeplearning/nihms-1767266.pdf"}],"documentFingerprint":"bfc9fa0d2dfeaf41b27539013de3cb13"},"uri":"vault:/hematology-theroy/papers/hematology_deeplearning/nihms-1767266.pdf","target":[{"source":"vault:/hematology-theroy/papers/hematology_deeplearning/nihms-1767266.pdf","selector":[{"type":"TextPositionSelector","start":68,"end":104},{"type":"TextQuoteSelector","exact":"Current Trends and Future Directions","prefix":"PET Imaging:: A Scoping Review (","suffix":")Navid Hasani1, Sriram S Paravas"}]}]}
>```
>%%
>*%%PREFIX%%PET Imaging:: A Scoping Review (%%HIGHLIGHT%% ==Current Trends and Future Directions== %%POSTFIX%%)Navid Hasani1, Sriram S Paravas*
>%%LINK%%[[#^mgh81iqaei8|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^mgh81iqaei8


>%%
>```annotation-json
>{"created":"2022-09-07T06:08:09.260Z","updated":"2022-09-07T06:08:09.260Z","document":{"title":"Artificial Intelligence in Lymphoma PET Imaging:: A Scoping Review (Current Trends and Future Directions)","link":[{"href":"urn:x-pdf:bfc9fa0d2dfeaf41b27539013de3cb13"},{"href":"vault:/hematology-theroy/papers/hematology_deeplearning/nihms-1767266.pdf"}],"documentFingerprint":"bfc9fa0d2dfeaf41b27539013de3cb13"},"uri":"vault:/hematology-theroy/papers/hematology_deeplearning/nihms-1767266.pdf","target":[{"source":"vault:/hematology-theroy/papers/hematology_deeplearning/nihms-1767266.pdf","selector":[{"type":"TextPositionSelector","start":2993,"end":3053},{"type":"TextQuoteSelector","exact":"022 January ; 17(1): 145–174. doi:10.1016/j.cpet.2021.09.006","prefix":"final edited form as:PET Clin. 2","suffix":".Author Manuscript Author Manusc"}]}]}
>```
>%%
>*%%PREFIX%%final edited form as:PET Clin. 2%%HIGHLIGHT%% ==022 January ; 17(1): 145–174. doi:10.1016/j.cpet.2021.09.006== %%POSTFIX%%.Author Manuscript Author Manusc*
>%%LINK%%[[#^9ziw3lqebc|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^9ziw3lqebc


>%%
>```annotation-json
>{"created":"2022-09-07T06:08:59.348Z","updated":"2022-09-07T06:08:59.348Z","document":{"title":"Artificial Intelligence in Lymphoma PET Imaging:: A Scoping Review (Current Trends and Future Directions)","link":[{"href":"urn:x-pdf:bfc9fa0d2dfeaf41b27539013de3cb13"},{"href":"vault:/hematology-theroy/papers/hematology_deeplearning/nihms-1767266.pdf"}],"documentFingerprint":"bfc9fa0d2dfeaf41b27539013de3cb13"},"uri":"vault:/hematology-theroy/papers/hematology_deeplearning/nihms-1767266.pdf","target":[{"source":"vault:/hematology-theroy/papers/hematology_deeplearning/nihms-1767266.pdf","selector":[{"type":"TextPositionSelector","start":3471,"end":3661},{"type":"TextQuoteSelector","exact":" 2-deoxy-2-[Fluorine-18]fluoro-D-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) is extensively used for staging and response assessment in HL and NHL.2, 3, 4, 5 ","prefix":"ange of clinical presentations.1","suffix":"The accurate and precise quantif"}]}]}
>```
>%%
>*%%PREFIX%%ange of clinical presentations.1%%HIGHLIGHT%% ==2-deoxy-2-[Fluorine-18]fluoro-D-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) is extensively used for staging and response assessment in HL and NHL.2, 3, 4, 5== %%POSTFIX%%The accurate and precise quantif*
>%%LINK%%[[#^clzoigbpv2m|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^clzoigbpv2m


>%%
>```annotation-json
>{"created":"2022-09-07T06:09:28.573Z","updated":"2022-09-07T06:09:28.573Z","document":{"title":"Artificial Intelligence in Lymphoma PET Imaging:: A Scoping Review (Current Trends and Future Directions)","link":[{"href":"urn:x-pdf:bfc9fa0d2dfeaf41b27539013de3cb13"},{"href":"vault:/hematology-theroy/papers/hematology_deeplearning/nihms-1767266.pdf"}],"documentFingerprint":"bfc9fa0d2dfeaf41b27539013de3cb13"},"uri":"vault:/hematology-theroy/papers/hematology_deeplearning/nihms-1767266.pdf","target":[{"source":"vault:/hematology-theroy/papers/hematology_deeplearning/nihms-1767266.pdf","selector":[{"type":"TextPositionSelector","start":4086,"end":4184},{"type":"TextQuoteSelector","exact":" Therefore, 18F-FDG PET/CT is extremely valuable in the noninvasive assessment of disease burden.1","prefix":"lammation8 as well as lymphoma.9","suffix":"0To determine global disease bur"}]}]}
>```
>%%
>*%%PREFIX%%lammation8 as well as lymphoma.9%%HIGHLIGHT%% ==Therefore, 18F-FDG PET/CT is extremely valuable in the noninvasive assessment of disease burden.1== %%POSTFIX%%0To determine global disease bur*
>%%LINK%%[[#^gub7jm7hyrl|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^gub7jm7hyrl


>%%
>```annotation-json
>{"created":"2022-09-07T06:09:51.333Z","updated":"2022-09-07T06:09:51.333Z","document":{"title":"Artificial Intelligence in Lymphoma PET Imaging:: A Scoping Review (Current Trends and Future Directions)","link":[{"href":"urn:x-pdf:bfc9fa0d2dfeaf41b27539013de3cb13"},{"href":"vault:/hematology-theroy/papers/hematology_deeplearning/nihms-1767266.pdf"}],"documentFingerprint":"bfc9fa0d2dfeaf41b27539013de3cb13"},"uri":"vault:/hematology-theroy/papers/hematology_deeplearning/nihms-1767266.pdf","target":[{"source":"vault:/hematology-theroy/papers/hematology_deeplearning/nihms-1767266.pdf","selector":[{"type":"TextPositionSelector","start":4221,"end":4796},{"type":"TextQuoteSelector","exact":"segmentation of all tumor lesions is a vital step that allows the measurement of metabolically active tumor volumes (MTV), mean activity of the lesion (SUVmean), lesion partial volume corrected metabolic volume product (PVC-MVP: calculated as the product of lesion MTV and lesion PVC-SUVmean), total metabolic tumor volume (TMTV: calculated as the sum of MTV of all lesions), total lesion glycolysis (TLG),11 whole-body metabolic burden (WBMB: calculated as the sum of lesion PVC-MVP of all lesions),10,12 metabolic heterogeneity (MH)13,14 and lesion dissemination (Dmax).15,","prefix":"etermine global disease burden, ","suffix":"16 There are, however, various m"}]}]}
>```
>%%
>*%%PREFIX%%etermine global disease burden,%%HIGHLIGHT%% ==segmentation of all tumor lesions is a vital step that allows the measurement of metabolically active tumor volumes (MTV), mean activity of the lesion (SUVmean), lesion partial volume corrected metabolic volume product (PVC-MVP: calculated as the product of lesion MTV and lesion PVC-SUVmean), total metabolic tumor volume (TMTV: calculated as the sum of MTV of all lesions), total lesion glycolysis (TLG),11 whole-body metabolic burden (WBMB: calculated as the sum of lesion PVC-MVP of all lesions),10,12 metabolic heterogeneity (MH)13,14 and lesion dissemination (Dmax).15,== %%POSTFIX%%16 There are, however, various m*
>%%LINK%%[[#^xa7h7fhpv18|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^xa7h7fhpv18


>%%
>```annotation-json
>{"created":"2022-09-07T07:23:08.275Z","updated":"2022-09-07T07:23:08.275Z","document":{"title":"Artificial Intelligence in Lymphoma PET Imaging:: A Scoping Review (Current Trends and Future Directions)","link":[{"href":"urn:x-pdf:bfc9fa0d2dfeaf41b27539013de3cb13"},{"href":"vault:/hematology-theroy/papers/hematology_deeplearning/nihms-1767266.pdf"}],"documentFingerprint":"bfc9fa0d2dfeaf41b27539013de3cb13"},"uri":"vault:/hematology-theroy/papers/hematology_deeplearning/nihms-1767266.pdf","target":[{"source":"vault:/hematology-theroy/papers/hematology_deeplearning/nihms-1767266.pdf","selector":[{"type":"TextPositionSelector","start":4809,"end":5418},{"type":"TextQuoteSelector","exact":" however, various methods for the segmentation of tumor lesions (e.g. manual, thresholding-based, region-based, or boundary-based)17,18 each with high inter-observer variability depending on the operator and segmentation method.19,20 Furthermore, even for an expert, manual segmentation takes time (30–45 minutes per patient depending on tumor burden) as summary measurements of each lesion must be aggregated.19 Lymphoma lesion segmentation is a challenging task due to the large variability in number, size, distribution, uptake, the shape of lesions, and different degrees of glucose metabolism (Fig. 1)21,","prefix":"mination (Dmax).15,16 There are,","suffix":" 22, 23 Normal biodistribution o"}]}]}
>```
>%%
>*%%PREFIX%%mination (Dmax).15,16 There are,%%HIGHLIGHT%% ==however, various methods for the segmentation of tumor lesions (e.g. manual, thresholding-based, region-based, or boundary-based)17,18 each with high inter-observer variability depending on the operator and segmentation method.19,20 Furthermore, even for an expert, manual segmentation takes time (30–45 minutes per patient depending on tumor burden) as summary measurements of each lesion must be aggregated.19 Lymphoma lesion segmentation is a challenging task due to the large variability in number, size, distribution, uptake, the shape of lesions, and different degrees of glucose metabolism (Fig. 1)21,== %%POSTFIX%%22, 23 Normal biodistribution o*
>%%LINK%%[[#^41cw6hnqepw|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^41cw6hnqepw


>%%
>```annotation-json
>{"created":"2022-09-07T07:23:35.017Z","updated":"2022-09-07T07:23:35.017Z","document":{"title":"Artificial Intelligence in Lymphoma PET Imaging:: A Scoping Review (Current Trends and Future Directions)","link":[{"href":"urn:x-pdf:bfc9fa0d2dfeaf41b27539013de3cb13"},{"href":"vault:/hematology-theroy/papers/hematology_deeplearning/nihms-1767266.pdf"}],"documentFingerprint":"bfc9fa0d2dfeaf41b27539013de3cb13"},"uri":"vault:/hematology-theroy/papers/hematology_deeplearning/nihms-1767266.pdf","target":[{"source":"vault:/hematology-theroy/papers/hematology_deeplearning/nihms-1767266.pdf","selector":[{"type":"TextPositionSelector","start":6058,"end":6239},{"type":"TextQuoteSelector","exact":"1) quantification of disease burden,26,27 (2) evaluation of therapy response,28 and (3) extraction of additional image information used for prognosis and diagnosis of lymphoma.29,30","prefix":"g lymphoma PET are as follows: (","suffix":" Artificial Intelligence (AI) ha"}]}]}
>```
>%%
>*%%PREFIX%%g lymphoma PET are as follows: (%%HIGHLIGHT%% ==1) quantification of disease burden,26,27 (2) evaluation of therapy response,28 and (3) extraction of additional image information used for prognosis and diagnosis of lymphoma.29,30== %%POSTFIX%%Artificial Intelligence (AI) ha*
>%%LINK%%[[#^ltgu82q2w7|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^ltgu82q2w7


>%%
>```annotation-json
>{"created":"2022-09-07T07:24:43.954Z","updated":"2022-09-07T07:24:43.954Z","document":{"title":"Artificial Intelligence in Lymphoma PET Imaging:: A Scoping Review (Current Trends and Future Directions)","link":[{"href":"urn:x-pdf:bfc9fa0d2dfeaf41b27539013de3cb13"},{"href":"vault:/hematology-theroy/papers/hematology_deeplearning/nihms-1767266.pdf"}],"documentFingerprint":"bfc9fa0d2dfeaf41b27539013de3cb13"},"uri":"vault:/hematology-theroy/papers/hematology_deeplearning/nihms-1767266.pdf","target":[{"source":"vault:/hematology-theroy/papers/hematology_deeplearning/nihms-1767266.pdf","selector":[{"type":"TextPositionSelector","start":12708,"end":12717},{"type":"TextQuoteSelector","exact":"Detection","prefix":"gy for Elucidating Algorithm Aim","suffix":"—Detection as a task refers to l"}]}]}
>```
>%%
>*%%PREFIX%%gy for Elucidating Algorithm Aim%%HIGHLIGHT%% ==Detection== %%POSTFIX%%—Detection as a task refers to l*
>%%LINK%%[[#^w31ug63pbuo|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^w31ug63pbuo
